Finding · criterion S3
What does 503A or 503B actually establish about a seller?
503A and 503B describe different federal compounding frameworks. Neither label identifies the filling facility by itself, and neither makes a compounded drug FDA-approved.
The distinction concerns the compounder
FDA's comparison explains that section 503A concerns qualifying compounding by licensed pharmacists in state-licensed pharmacies or federal facilities, or by licensed physicians. Patient-specific prescriptions are central to that framework. Section 503B concerns registered outsourcing facilities and permits qualifying compounding without patient-specific prescriptions.
The frameworks differ in their conditions and exemptions. Current good manufacturing practice requirements apply to outsourcing facilities. A label saying 503B therefore describes a different regulatory arrangement from a general reference to a local compounding pharmacy. It does not communicate an approval decision about the medicine being advertised.
Registration needs a facility match
FDA defines an outsourcing facility at a particular geographic location. Its registration information can be checked against the name and address a seller provides. A company with more than one operation may have different facilities operating under different arrangements.
That makes a bare claim such as our 503B partners incomplete. It does not identify the address supplying an order. A meaningful record links the storefront statement to a specific facility, while preserving uncertainty about any product or shipment that the public pages do not identify.
Three questions remain separate
The first question is who prescribes. The second is who compounds or dispenses. The third is what regulatory status the particular product has. Answering one does not automatically settle the other two. A telehealth seller can explain its clinical process well while withholding the pharmacy name.
Peptide Alliance treats the pharmacy identification criterion and compounding disclosure criterion separately for this reason. The record can recognize a named facility and still identify incomplete wording about the product. A useful comparison keeps the actual company statement beside the source, rather than assigning a blanket safe or unsafe label to all products associated with one category.
Related standard: S3. Pharmacy identification. Evidence for individual companies appears in the seller ledger.
Related reading
Sources
- FDA: provisions that apply to human drug compounding
- FDA: information for outsourcing facilities
- FDA: registered outsourcing facilities
Related findings
Compounded GLP-1 labels: concentration, volume and unitsSyringe units, liquid volume and the amount of medication describe different things. A familiar syringe marking cannot establish a dose when the concentration or prescription has changed. Ask the dispensing pharmacist to reconcile the prescription, label and supplied syringe.
How can a named compounding pharmacy be verified?Start with the dispensing pharmacy's exact name and address, then compare them with the relevant state pharmacy board record. A seller's logo or partner list is insufficient.
How many peptide sellers name the pharmacy that fills the order?A minority. Most sellers substitute a legal category, such as a licensed 503A pharmacy, for a facility a reader could look up in a state board register.
Which pharmacies fill the orders, and how many sellers name the same one?Fewer facilities than storefronts. Several sellers that look like separate businesses name the same filling pharmacy, and one facility appears in the ledger under several different spellings, each written by a different seller.